<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385630</url>
  </required_header>
  <id_info>
    <org_study_id>CRFSJ 0058</org_study_id>
    <secondary_id>2014-12 CA</secondary_id>
    <nct_id>NCT02385630</nct_id>
  </id_info>
  <brief_title>Longitudinal Assessment of Gut Hormone Secretion Following Upper Gastrointestinal Surgery for Cancer</brief_title>
  <official_title>Longitudinal Assessment of Gut Hormone Secretion Following Upper Gastrointestinal Surgery for Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. James's Hospital, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dublin, Trinity College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. James's Hospital, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery is the cornerstone of treatment for patients with oesophageal or gastric cancer, but
      while surgical removal of the tumour (oesophagectomy or gastrectomy) may offer the best
      chance of cure, these are major operations associated with specific long term complications.
      Weight loss and poor nutrition are relatively common problems among patients who attain
      long-term cancer remission and cure after surgery. The mechanisms underlying these problems
      are not well understood and therefore treatment options are limited.

      The investigators research has demonstrated increased levels of chemical messengers (gut
      hormones) released from the gastrointestinal tract after meals in patients who have
      previously undergone upper gastrointestinal surgery. These chemical messengers play a role in
      signalling the feeling of fullness during and after a meal (satiety). Understanding the
      mechanisms involved in increased gut hormone secretion after these operations may allow us to
      use certain medications to block gut hormone release and hence reduce satiety allowing
      patients to eat more, regain weight and prevent nutritional complications after surgery.

      Exaggerated post-prandial satiety gut hormone responses following oesophagectomy have,
      however, only been established cross-sectionally and therefore the time course for
      development of increased gut hormone secretion is unknown. Data collected from this study
      will provide important information about optimal timing of therapeutic intervention in this
      patient group, while offering mechanistic insights with regard to the pathophysiologic
      process underlying post-operative early satiety.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-prandial satiety gut hormone area under the curve</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body antropometry</measure>
    <time_frame>1 year</time_frame>
    <description>Weight (kg), height, waist circumference, hip circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>EORTC QLQ-30, OG25, OES 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective symptom scores</measure>
    <time_frame>1 year</time_frame>
    <description>Sigstad dumping score, modified visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting ghrelin concentration</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Stomach Neoplasms</condition>
  <condition>Weight Loss</condition>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>Esophagectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serial assessment:
Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serial assessment:
Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized 400kcal semi-liquid meal</intervention_name>
    <description>Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.</description>
    <arm_group_label>Esophagectomy</arm_group_label>
    <arm_group_label>Gastrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo two-stage, three-stage or transhiatal oesophagectomy
             with gastric conduit reconstruction OR total gastrectomy with Roux-en-Y reconstruction

        Exclusion Criteria:

          1. Significant and persistent chemoradiotherapy complication

          2. Other previous upper gastrointestinal surgery

          3. Unwell or unable to eat

          4. Other disease or medications which may affect satiety gut hormone responses

          5. Active and significant psychiatric illness including substance misuse

          6. Cognitive or communication issues or any factors affecting capacity to consent to
             participation

          7. History of significant food allergy, certain dietary restrictions

          8. Confirmed or suspected residual or recurrent disease after surgery, synchronous or
             metachronous malignancy

          9. Significant surgical complication, aspiration risk or deterioration in performance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John V Reynolds, MCh, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, St. James's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wellcome Trust-Health Research Board Clinical Research Facility, St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <link>
    <url>http://www.sjhcrf.ie</url>
    <description>Wellcome Trust-HRB Clinical Research Facility</description>
  </link>
  <link>
    <url>http://www.ucd.ie/conway/</url>
    <description>Conway Institute of Biomolecular and Biomedical Research</description>
  </link>
  <link>
    <url>https://medicine.tcd.ie/surgery/</url>
    <description>Department of Surgery, Trinity College Dublin and St. James's Hospital</description>
  </link>
  <reference>
    <citation>Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P. Malnutrition after oesophageal cancer surgery in Sweden. Br J Surg. 2007 Dec;94(12):1496-500.</citation>
    <PMID>17668914</PMID>
  </reference>
  <reference>
    <citation>Martin L, Lagergren P. Long-term weight change after oesophageal cancer surgery. Br J Surg. 2009 Nov;96(11):1308-14. doi: 10.1002/bjs.6723.</citation>
    <PMID>19847871</PMID>
  </reference>
  <reference>
    <citation>Donohoe CL, McGillycuddy E, Reynolds JV. Long-term health-related quality of life for disease-free esophageal cancer patients. World J Surg. 2011 Aug;35(8):1853-60. doi: 10.1007/s00268-011-1123-6.</citation>
    <PMID>21553202</PMID>
  </reference>
  <reference>
    <citation>Yamamoto K, Takiguchi S, Miyata H, Adachi S, Hiura Y, Yamasaki M, Nakajima K, Fujiwara Y, Mori M, Kangawa K, Doki Y. Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery. 2010 Jul;148(1):31-8. doi: 10.1016/j.surg.2009.11.026. Epub 2010 Jan 21.</citation>
    <PMID>20096432</PMID>
  </reference>
  <reference>
    <citation>Miyazaki T, Tanaka N, Hirai H, Yokobori T, Sano A, Sakai M, Inose T, Sohda M, Nakajima M, Fukuchi M, Kato H, Kuwano H. Ghrelin level and body weight loss after esophagectomy for esophageal cancer. J Surg Res. 2012 Jul;176(1):74-8. doi: 10.1016/j.jss.2011.09.016. Epub 2011 Oct 3.</citation>
    <PMID>22137988</PMID>
  </reference>
  <reference>
    <citation>Koizumi M, Hosoya Y, Dezaki K, Yada T, Hosoda H, Kangawa K, Nagai H, Lefor AT, Sata N, Yasuda Y. Postoperative weight loss does not resolve after esophagectomy despite normal serum ghrelin levels. Ann Thorac Surg. 2011 Apr;91(4):1032-7. doi: 10.1016/j.athoracsur.2010.11.072.</citation>
    <PMID>21440118</PMID>
  </reference>
  <reference>
    <citation>Doki Y, Takachi K, Ishikawa O, Miyashiro I, Sasaki Y, Ohigashi H, Nakajima H, Hosoda H, Kangawa K, Sasakuma F, Motoori M, Imaoka S. Ghrelin reduction after esophageal substitution and its correlation to postoperative body weight loss in esophageal cancer patients. Surgery. 2006 Jun;139(6):797-805.</citation>
    <PMID>16782437</PMID>
  </reference>
  <reference>
    <citation>le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lönroth H, Fändriks L, Ghatei MA, Bloom SR, Olbers T. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007 Nov;246(5):780-5.</citation>
    <PMID>17968169</PMID>
  </reference>
  <reference>
    <citation>Papamargaritis D, le Roux CW, Sioka E, Koukoulis G, Tzovaras G, Zacharoulis D. Changes in gut hormone profile and glucose homeostasis after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2013 Mar-Apr;9(2):192-201. doi: 10.1016/j.soard.2012.08.007. Epub 2012 Aug 24.</citation>
    <PMID>23183113</PMID>
  </reference>
  <reference>
    <citation>Miholic J, Orskov C, Holst JJ, Kotzerke J, Pichlmayr R. Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection. Digestion. 1993;54(2):73-8.</citation>
    <PMID>8319842</PMID>
  </reference>
  <reference>
    <citation>le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R, Ghatei MA, Patel A, Bloom SR, Aylwin SJ. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg. 2010 Jul;252(1):50-6. doi: 10.1097/SLA.0b013e3181d3d21f.</citation>
    <PMID>20562614</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. James's Hospital, Ireland</investigator_affiliation>
    <investigator_full_name>Dr Jessie A Elliott</investigator_full_name>
    <investigator_title>Surgical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Longitudinal Studies</keyword>
  <keyword>Esophagectomy</keyword>
  <keyword>Gastrectomy</keyword>
  <keyword>Hunger</keyword>
  <keyword>Appetite</keyword>
  <keyword>Glucagon-like Peptide 1</keyword>
  <keyword>Peptide YY</keyword>
  <keyword>Ghrelin</keyword>
  <keyword>Satiety Response</keyword>
  <keyword>Feeding Behavior</keyword>
  <keyword>Meals</keyword>
  <keyword>Postprandial Period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

